The lack of demand for Abbott’s (ABT) COVID-19 tests has been limiting overall growth. Foreign exchange fluctuations continue to hamper growth as well. The stock carries a Zacks Rank #4 (Sell) currently.Following the official ending of the public health emergency in 2023, Abbott has been experiencing a continuous decline in COVID testing-related demand. In Rapid Diagnostics, sales decreased 49.2% in the fourth quarter of 2023, excluding the effect of foreign exchange, due to the lower demand for COVID-19 te ...

Abbott Laboratories, Inc. (ABT) recently secured the FDA’s approval for the TriClip transcatheter edge-to-edge repair (TEER) system, which is specifically designed for the treatment of tricuspid regurgitation (TR) or a leaky tricuspid valve. This approval follows the recent recommendation of the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the FDA, whose vote confirmed 13 to 1, with 0 abstentions, that the benefits of TriClip outweighed the risks.The approval helps address ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT) .Abbott currently has an average brokerage recommendation (AB ...

Abbott Laboratories, Inc. (ABT) recently announced the receipt of the FDA approval for the i-STAT TBI (traumatic brain injury) cartridge.  The test runs on Abbott's portable i-STAT Alinity instrument, which uses whole blood to help assess patients with a suspected mild traumatic brain injury (mTBI) or concussion. The test delivers lab-quality results in 15 minutes.The latest development expands Abbott's TBI test offering, fortifying its Diagnostics business.More on for i-STAT TBI cartridgeAbbott's i-STAT TB ...

The latest trading session saw Abbott (ABT) ending at $112.09, denoting a -1.38% adjustment from its last day's close. This change lagged the S&P 500's 0.2% loss on the day. Elsewhere, the Dow saw a downswing of 0.6%, while the tech-heavy Nasdaq appreciated by 0.11%.Shares of the maker of infant formula, medical devices and drugs witnessed a loss of 4.18% over the previous month, trailing the performance of the Medical sector with its gain of 2.21% and the S&P 500's gain of 3.32%.Market participants will be ...

Dividend-paying stocks have generally outperformed those that don't pay dividends over the long term. That's partly because maintaining a healthy dividend requires a solid underlying business. And investors who reinvest those dividends can significantly boost their long-term returns.That said, not every company that pays a dividend is capable of consistency. Many find it necessary in hard times to decrease their payouts or suspend them altogether. Two that are unlikely to do either of those things anytime s ...

Inflation came in much hotter than expected in February. Core services inflation, which excludes housing, rose 0.5% from January following a 0.9% increase from December. Last month’s gain was twice as fast as it was pre-pandemic, causing the Federal Reserve to rethink interest cutting rate too soon.Consumer spending is weakening as real disposable income fell in January. At the same time, household debt hit an unsustainable $17.5 trillion. Credit card and auto loan debt is also at record levels and rising, ...

As the world economy teeters on the verge of instability, three titans have survived many financial storms and emerged stronger than ever from the waves of uncertainty. Here, recognizing these business titans’ strategic acumen reveals a means to protect riches. Every firm has a different story of perseverance, but all are united by a persistent dedication to maximizing shareholder value in the face of hardship.With its strategy focusing on sales growth, margin expansion and operational efficiency, the first ...

The latest trading session saw Abbott (ABT) ending at $111.50, denoting a -1.47% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 0.89%. At the same time, the Dow added 1.03%, and the tech-heavy Nasdaq gained 1.25%.Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 2.98% over the past month. This has lagged the Medical sector's gain of 0.72% and the S&P 500's gain of 3.56% in that time.The upcoming earnings release of Abbott ...

In the latest market close, Abbott (ABT) reached $113.16, with a +0.64% movement compared to the previous day. This change outpaced the S&P 500's 0.57% gain on the day. Elsewhere, the Dow saw an upswing of 0.83%, while the tech-heavy Nasdaq appreciated by 0.39%.The maker of infant formula, medical devices and drugs's shares have seen a decrease of 1.38% over the last month, not keeping up with the Medical sector's gain of 0.13% and the S&P 500's gain of 2.97%.Investors will be eagerly watching for the perfo ...